Trial Profile
An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 29 Dec 2021 Status changed from active, no longer recruiting to completed.
- 29 Dec 2021 Status changed from active, no longer recruiting to completed.
- 24 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.